Form 4: Day One Biopharmaceuticals Acquired by Servier

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals in an all-cash transaction at $21.50 per share.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) completed its merger with Servier Pharmaceuticals LLC on April 23, 2026.
• Under the terms of the agreement, all outstanding shares of common stock were purchased for $21.50 per share in cash.
• All outstanding unvested stock options and restricted stock units (RSUs) were fully vested immediately prior to the merger.
• All equity awards were canceled and converted into the right to receive the merger consideration, net of applicable exercise prices and withholding taxes.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the filing confirms the successful completion of a definitive acquisition agreement at a fixed cash price.

Positives

• Shareholders received a definitive cash exit at $21.50 per share.
• Full acceleration of vesting for all outstanding employee and executive equity awards upon the merger closing.

Negatives

• The company ceases to exist as an independent publicly traded entity following the acquisition.

Risks

• No ongoing risks as the company has been acquired and is now a wholly owned subsidiary.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals; no further independent public guidance is provided.

Management Comments

• The filing confirms the execution of the merger agreement and the subsequent conversion of all equity interests into cash.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large pharmaceutical companies acquiring specialized biotech firms to bolster their oncology and rare disease pipelines.

Comparison to Industry Standards

• The all-cash acquisition structure is standard for mid-cap biotech exits.
• The acceleration of equity vesting is a common provision in change-of-control agreements to align management interests with the acquisition.

Legal Proceedings

• None mentioned; the transaction was completed pursuant to a signed Merger Agreement.

Related Party Transactions

• The reporting person held shares through various Grantor Retained Annuity Trusts and a Revocable Trust, all of which were settled as part of the merger.

Stakeholder Impact

• Shareholders receive cash liquidity for their holdings.
• Employees and executives benefit from the immediate vesting of equity awards.

Next Steps

• Delisting of DAWN common stock from public exchanges.
• Integration of Day One Biopharmaceuticals into Servier Pharmaceuticals operations.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Servier Pharmaceuticals, Merger, Acquisition, SEC Form 4, Biotech